AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10516117 — intervention group
Group type: COMPARATOR
Intervention: Late group
Number of subjects: 16
Study 7752754 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU)
Number of subjects: 336
Study 7752754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 2042789 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 micrograms.kg‐1, infused over 15 min
Number of subjects: 40
Study 2042789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7015989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g/day
Number of subjects: 26
Study 7015989 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate 4 mg/day
Number of subjects: 26
Study 30073290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily for 8 weeks
Number of subjects: 200
Study 30073290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 30073290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 200
Study 28376440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 25687957 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Training (RT)
Number of subjects: 40
Study 25687957 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 40
Study 23715049 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI withdrawal
Number of subjects: 119
Study 23715049 — intervention group
Group type: COMPARATOR
Intervention: MMF withdrawal
Number of subjects: 119
Study 20533634 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond, no contamination (control group)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 1 (CG1): primer application/ contamination/primer re‐application
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 2 (CG2): primer application/contamination/wash/dry/primer re‐application
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 3 (CG3): primer application/adhesive application/light curing/contamination/ adhesive re‐application/light curing
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond, contamination group 4 (CG4): primer application/adhesive application/light curing/contamination/wash/dry/adhesive re‐application/light curing
Number of subjects: 60
Study 20533634 — intervention group
Group type: COMPARATOR
Intervention: AdheSE, no contamination (control group)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 1 (CG1)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 2 (CG2)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 3 (CG3)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE, contamination group 4 (CG4)
Number of subjects: 60
Study 20533634 — intervention group
Group type: COMPARATOR
Intervention: Tyrian SPE, no contamination (control group)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 1 (CG1)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 2 (CG2)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 3 (CG3)
Number of subjects: 60
Study 20533634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE, contamination group 4 (CG4)
Number of subjects: 60
Study 18262146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 47
Study 18262146 — intervention group
Group type: COMPARATOR
Intervention: Control (no pentoxifylline)
Number of subjects: 47
Study 16606645 — intervention group
Group type: EXPERIMENTAL
Intervention: Single DMARD treatment with or without prednisolone (single group)
Number of subjects: 169
Study 16606645 — intervention group
Group type: COMPARATOR
Intervention: Combination DMARD treatment with prednisolone (combination group)
Number of subjects: 169
Study 12950963 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbents Recirculating System (MARS)
Number of subjects: 23
Study 12950963 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 23
Study 10385132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 40 mg, three times daily orally for 2 days
Number of subjects: 11
Study 10385132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8598702 — intervention group
Group type: COMPARATOR
Intervention: Trials published in English
Number of subjects: 229
Study 8598702 — intervention group
Group type: COMPARATOR
Intervention: Trials published in other languages
Number of subjects: 229
Study 8598702 — intervention group
Group type: COMPARATOR
Intervention: Other-language trials
Number of subjects: 229
Study 1760831 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sustained-release IS-5-MN
Number of subjects: 28
Study 1760831 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg sustained-release IS-5-MN
Number of subjects: 28
Study 1760831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages
Number of subjects: 28
Study 1760831 — intervention group
Group type: EXPERIMENTAL
Intervention: Elantan Long (50 mg sustained-release IS-5-MN)
Number of subjects: 28
Study 1760831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6760653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 100 mg twice daily for 12 weeks
Number of subjects: 21
Study 6760653 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 21
Study 6760653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 21
Study 2932485 — intervention group
Group type: EXPERIMENTAL
Intervention: nomifensine
Number of subjects: 42
Study 2932485 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 42
Study 2932485 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study 29958455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index Diet (LGID)
Number of subjects: 163
Study 29958455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 163
Study 29958455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index Mediterranean Diet (LGIMD)
Number of subjects: 163
Study 29958455 — intervention group
Group type: COMPARATOR
Intervention: Control group (without MetS)
Number of subjects: 163
Study 26400923 — intervention group
Group type: EXPERIMENTAL
Intervention: active intermittent theta burst stimulation (iTBS)
Number of subjects: 19
Study 26400923 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 19
Study 24439984 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 22 mg daily
Number of subjects: 44
Study 24439984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22001561 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Number of subjects: 34
Study 22001561 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 34
Study 22001561 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 34
Study 20052606 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a 1‐m saltwater crocodile before playing the EGM
Number of subjects: 103
Study 20052606 — intervention group
Group type: COMPARATOR
Intervention: Control group (playing EGM prior to holding the crocodile)
Number of subjects: 103
Study 19323355 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear frequency transposition with 30 minutes of training
Number of subjects: 9
Study 19323355 — intervention group
Group type: COMPARATOR
Intervention: Conventional amplification
Number of subjects: 9
Study 16873938 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation (100 mg tid for 4 weeks)
Number of subjects: 21
Study 16873938 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation
Number of subjects: 21
Study 12424684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (2 mg/kg bodyweight)
Number of subjects: 60
Study 12424684 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin
Number of subjects: 60
Study 10939029 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 53
Study 10939029 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 53
Study 7562758 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rodnan skin thickness score (0-3 scale)
Number of subjects: 8
Study 7562758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced number of sites (5 sites: forearms, lower legs, anterior chest, upper arms, fingers)
Number of subjects: 8
Study 2187941 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial inferior turbinectomy
Number of subjects: 80
Study 2187941 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser turbinectomy
Number of subjects: 80
Study 2187941 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbinoplasty
Number of subjects: 80
Study 2187941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoturbinectomy
Number of subjects: 80
Study 7033945 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 0
Study 7033945 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide
Number of subjects: 0
Study 31916906 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet regarding HPV vaccination and a second leaflet recommending discussion with husbands (Group A)
Number of subjects: 1499
Study 31916906 — intervention group
Group type: COMPARATOR
Intervention: Educational leaflet regarding HPV vaccination only (Group B)
Number of subjects: 1499
Study 31916906 — intervention group
Group type: COMPARATOR
Intervention: No leaflets (Group C)
Number of subjects: 1499
Study 31916906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Educational leaflet + husband discussion)
Number of subjects: 1499
Study 31916906 — intervention group
Group type: COMPARATOR
Intervention: Group B (Educational leaflet only)
Number of subjects: 1499
Study 31916906 — intervention group
Group type: COMPARATOR
Intervention: Group C (No leaflets)
Number of subjects: 1499
Study 30726689 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline (100 mg IV every 12 hours for two doses, then 100 mg IV every 24 hours; transition to oral 300 mg every 24 hours after 3 days allowed)
Number of subjects: 627
Study 30726689 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg IV every 12 hours; transition to oral 600 mg every 12 hours after 3 days allowed)
Number of subjects: 627
Study 30726689 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 627
Study 30726689 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 627
Study 29856291 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide used when other therapies failed; previously prescribed octreotide for this clinical indication.
Number of subjects: 106
Study 29856291 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 106
Study 29856291 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (clinician age 50-59 years).
Number of subjects: 106
Study 29856291 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower proportions of people treated with octreotide (0%-20%).
Number of subjects: 106
Study 26563147 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Cognitive Behavioral Therapy (MI-CBT)
Number of subjects: 81
Study 26563147 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 81
Study 26563147 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT (after crossover from TAU)
Number of subjects: 81
Study 26563147 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT
Number of subjects: 81
Study 24828790 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angioplasty
Number of subjects: 266
Study 24828790 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 266
Study 23127770 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months i.m. leuprorelin prior to radiotherapy followed by 12 months i.m. leuprorelin and 18 months i.v. zoledronic acid (Z)
Number of subjects: 1071
Study 23127770 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (HDRB) boost
Number of subjects: 1071
Study 23127770 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant androgen suppression, bisphosphonates, and increasing EBRT dose
Number of subjects: 1071
Study 20927698 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (400-600 mg/day tapering to 100-300 mg/day)
Number of subjects: 40
Study 20927698 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (130-50 mg/day tapering to 5-15 mg/day)
Number of subjects: 40
Study 18372685 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exposure to a +Gz acceleration gradient
Number of subjects: 0
Study 18372685 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring tools used during centrifuge spin
Number of subjects: 0
Study 15791505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis (levofloxacin)
Number of subjects: 9
Study 15791505 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of fluoroquinolone prophylaxis
Number of subjects: 9
Study 15791505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis (levofloxacin) reintroduced
Number of subjects: 9
Study 11040765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-cut teat
Number of subjects: 0
Study 11040765 — intervention group
Group type: COMPARATOR
Intervention: Standard single-hole teat
Number of subjects: 0
Study 9069060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Number of subjects: 15
Study 9069060 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 15
Study 8325405 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture removal at 12 weeks
Number of subjects: 135
Study 8325405 — intervention group
Group type: COMPARATOR
Intervention: Suture removal at 6 or 9 weeks
Number of subjects: 135
Study 3016764 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking two marijuana cigarettes (2.8% THC)
Number of subjects: 4
Study 3016764 — intervention group
Group type: COMPARATOR
Intervention: Smoking one marijuana cigarette and one placebo cigarette
Number of subjects: 4
Study 3016764 — intervention group
Group type: COMPARATOR
Intervention: Smoking two placebo cigarettes
Number of subjects: 4
Study 3016764 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective effects measures (Addiction Research Center Inventory, Single Dose Questionnaire, Visual Analog Scale)
Number of subjects: 4
Study 3016764 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor performance task
Number of subjects: 4
Study 29308549 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Coping Power (ICP)
Number of subjects: 360
Study 29308549 — intervention group
Group type: COMPARATOR
Intervention: Group Coping Power (GCP)
Number of subjects: 360
Study 29308549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICP and GCP
Number of subjects: 360
Study 28028674 — intervention group
Group type: EXPERIMENTAL
Intervention: MacVL with real-time feedback
Number of subjects: 60
Study 28028674 — intervention group
Group type: EXPERIMENTAL
Intervention: MacVL with real-time feedback plus video recordings
Number of subjects: 60
Study 28028674 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (Control)
Number of subjects: 60
Study 28028674 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups tested using Macintosh direct laryngoscope
Number of subjects: 60
Study 26002761 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (dopamine agonist patch with 24-hour action)
Number of subjects: 256
Study 26002761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 23090292 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO(3) and CHO (B-CHO)
Number of subjects: 6
Study 23090292 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO(3) (B-P)
Number of subjects: 6
Study 23090292 — intervention group
Group type: COMPARATOR
Intervention: Placebo and CHO (P-CHO)
Number of subjects: 6
Study 23090292 — intervention group
Group type: COMPARATOR
Intervention: Placebo and an artificial sweetener (P-P)
Number of subjects: 6
Study 21572315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-nose breathing (MNB)
Number of subjects: 20
Study 21572315 — intervention group
Group type: COMPARATOR
Intervention: Mouth-to-mouth breathing (MMB)
Number of subjects: 20
Study 20079321 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg adalimumab
Number of subjects: 302
Study 20079321 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg adalimumab
Number of subjects: 302
Study 20079321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 20079321 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 302
Study 20079321 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 302
Study 16979327 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (petal) 30 mg/day (BD)
Number of subjects: 40
Study 16979327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BD)
Number of subjects: 40
Study 15580395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. in fasted state
Number of subjects: 25
Study 15580395 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million i.u. recombinant interferon alpha-2b (IFNA) administered s.c. after semiliquid test meal
Number of subjects: 25
Study 15580395 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered s.c. in fasted state
Number of subjects: 25
Study 15580395 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered s.c. after semiliquid test meal
Number of subjects: 25
Study 11245552 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive (DSG-OC)
Number of subjects: 41
Study 11245552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9313879 — intervention group
Group type: COMPARATOR
Intervention: AML patients
Number of subjects: 26
Study 9313879 — intervention group
Group type: COMPARATOR
Intervention: AML stromal layers
Number of subjects: 26
Study 8359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg bisulfate) co-administration with Haloperidol (5 mg)
Number of subjects: 13
Study 8359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg bisulfate) co-administration with Reduced Haloperidol (5 mg)
Number of subjects: 13
Study 8359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (250 mg bisulfate) co-administration
Number of subjects: 13
Study 8359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg) and Reduced Haloperidol (5 mg)
Number of subjects: 13
Study 8359179 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 13
Study 3521427 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell-depleted bone marrow (using monoclonal anti-T-cell antibody CT-2 and complement)
Number of subjects: 40
Study 3521427 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-T-cell-depleted bone marrow)
Number of subjects: 40
Study 3521427 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell-depleted bone marrow
Number of subjects: 40
Study 3521427 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 3521427 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections and overall survival
Number of subjects: 40
Study 31895257 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory anesthetic device (VAD ON)
Number of subjects: 87
Study 31895257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (VAD OFF)
Number of subjects: 87
Study 30293771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 12000
Study 30293771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study 28495264 — intervention group
Group type: COMPARATOR
Intervention: Routine polio programme activities (Control, arm A)
Number of subjects: 28784
Study 28495264 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional interventions with community outreach and mobilisation (arm B)
Number of subjects: 28784
Study 28495264 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions of arm B with additional provision of IPV (arm C)
Number of subjects: 28784
Study 26402941 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral oxygen therapy (oxygen smoothies based on protein-carbohydrate raw materials with dietary fiber), 500 ml daily for 10 days.
Number of subjects: 60
Study 26402941 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral oxygen therapy (oxygen smoothies)
Number of subjects: 60
Study 26402941 — intervention group
Group type: COMPARATOR
Intervention: Aerated non-oxygen mixture (placebo)
Number of subjects: 60
Study 22983681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural stress management
Number of subjects: 28
Study 22983681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 21181639 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-weight bearing (NWB) gastrocnemius stretching
Number of subjects: 28
Study 21181639 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing (WB) gastrocnemius stretching
Number of subjects: 28
Study 18805509 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily (BID) call schedule
Number of subjects: 71
Study 18805509 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) call schedule
Number of subjects: 71